Cardiomyopathy is a leading cause of heart failure in children, and there are currently no effective treatments. Could emerging therapies that successfully target the root cause of the condition in adults also work well in children? That was the question Dr....
In the realm of cardiac health, an exciting new study has cast light on the intricate details of our hearts, revealing significant differences between the left and right ventricles' fibroblasts. This research, conducted by a team of dedicated scientists from the...
For children diagnosed with complex heart conditions like hypertrophic cardiomyopathy (HCM), the diagnosis can be frightening for families and challenging for healthcare providers since the trajectory of the condition is often uncertain. As a leading cause of sudden...
An innovative cardiovascular start-up, HDAX Therapeutics, is the latest company to win $250,000 in funding following another year of the Ted Rogers Centre for Heart Research’s Entrepreneurship for Cardiovascular Health Opportunities (ECHO) program. The ECHO program...
Several members of the Ted Rogers Centre for Heart Research (TRCHR) participated in Vascular 2023, a five-day conference held in Montreal from October 25-29. The conference is a hallmark event organized by several Canadian specialist and research organizations,...
Researchers at the Ted Rogers Centre for Heart Research have developed an innovative approach to better understanding the complex signaling mechanisms underlying heart failure. A recent publication in the Proceedings of the National Academy of Sciences (PNAS) offers...
While we are mandated to develop new collaborations within our partner institutions – The Hospital for Sick Children, University Health Network and the University of Toronto – we welcome any innovative ideas and opportunities for collaboration that support our mission.
The pursuit of that mission lies in multidisciplinary experts working together to develop new projects and innovations. To that end, our teams spread across genomics, AI, biosensor technologies, systems biology, congenital heart disease, clinical heart failure care, regenerative medicine, immunology, bioengineering, cardiac tissues and cellular systems, cardiotoxicity, virtual care, and more.
World-leading researchers: We are embedded in the health-care and tech hub of Toronto, and our teams work in globally recognized institutions. SickKids is one of the world’s top pediatric hospitals. UHN is Canada’s largest research hospital, with cardiology one of its prime foci. U of T is routinely among the world’s top universities for research.
Willingness to explore bold ideas: Our Centre is devoted to entirely novel innovations. We conduct and fund research projects that carry the greatest likelihood to translate into clinical practice. Our leadership and advisors ensure we are advancing at all times, testing the true limits of potential for new ideas.
Collaborative mentality: Partners gain access to the powers of collaboration and simultaneous expertise in genetics, stem cells and regenerative medicine, and advanced clinical innovations in cardiovascular care. This tandem approach generates rare and promising opportunities for industry.
Focus on translation: We understand that IP stemming from basic or academic research often requires further refinement in order to interest potential investors or companies. Our structure, including a Translation and Commercialization Committee, is designed to bring real products to market.
Potential impact: The Centre’s prime focus is heart failure, one of the world’s most challenging and widespread chronic diseases. Our partners have the opportunity to make meaningful change in the lives of 1 million Canadians with heart failure, and well beyond.
Write to us: communications@trchr.ca